Conclusions
1 evidence topic · 3 sources
Summary
FDA acceptance of the BLA and Priority Review do not establish approval. The reported target action date is January 21, 2027. The application uses dystrophin as a surrogate endpoint; the available functional comparisons remain exploratory. FORZETTO is the confirmatory Phase 3 trial. No product-specific budget impact model or acquisition price is available in the evidence reproduced here.